Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Verisign, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B), while Verisign, Inc. trades at $283.33 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 2.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Verisign, Inc. pays a 1.13% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VRSN | |
|---|---|---|
Market Cap | $9.43B | $26.00B |
Sector | Health | Technology |
52-Week High | $356.25 | $310.00 |
52-Week Low | $241.71 | $211.49 |
Enterprise Value | $9.18B | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
VeriSign (VRSN) trades at $293.34, down 0.41% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with record domain registrations and 6% revenue growth, maintaining robust profit margins near 50%. Recent delegation of .web domain and AI-driven registration growth provide positive catalysts.
The stock offers 9% upside to consensus price target of $320 with 60% analyst buy ratings. Key risks include contract renewals and premium valuation at 31x P/E. Strong cash flow generation and dividend payments support shareholder returns amid stable internet infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
